Radiofrequenzablation bei tumoren der lunge und mediastinalen lymphknoten
[Radiofrequency ablation of tumours of the lung and mediastinal lymph nodes]
Warmuth M, Nachtnebel A

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
Radiofrequency ablation (RFA) is a relatively new, minimally-invasive ablation method that destroys tumors by local application of heat. This systematic review evaluates the following indications of RFA for the treatment of thoracic tumors: primary lung cancer, lung metastases (associated with primary carcinomas of the breast, prostate, colon and rectum) and tumors of mediastinal lymph nodes.

Authors' conclusions
According to GRADE, the quality of evidence of the included RCT is very low due to major methodological flaws. Moreover, the quality of evidence of the included case-series is very low due their uncontrolled study design. Overall, the available evidence is insufficient to assess the efficacy and safety of RFA compared to the respective standard therapy for the treatment of lung tumors. Additionally, there is no evidence concerning RFA for the treatment of tumors of mediastinal lymph nodes. Currently, the inclusion into the hospital benefit catalogue is not recommended.

Final publication URL
http://eprints.hta.lbg.ac.at/957/1/DSD_53.pdf

Indexing Status
Subject indexing assigned by CRD

MeSH
Lung Neoplasms; Catheter Ablation; Lymph Nodes

Language Published
German

Country of organisation
Austria

English summary
An English language summary is available.

Address for correspondence
Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 Email: marisa.warmuth@hta.lbg.ac.at

AccessionNumber
32012000770
Date abstract record published
13/10/2012